Cargando…

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program

BACKGROUND: Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL). METHODS: Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B, Rosen, Noah L, Ailani, Jessica, DeGryse, Ronald E, Gillard, Patrick J, Varon, Sepideh F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959035/
https://www.ncbi.nlm.nih.gov/pubmed/27288354
http://dx.doi.org/10.1177/0333102416652092